Bispecific repurposed medicines targeting the viral and immunological arms of COVID-19.

ABSTRACT: Effective agents to treat coronavirus infection are urgently required, not only to treat COVID-19, but to prepare for future outbreaks. Repurposed anti-virals such as remdesivir and human anti-inflammatories such as barcitinib have received emergency approval but their overall benefits remain unclear. Vaccines are the most promising prospect for COVID-19, but will need to be redeveloped for any future coronavirus outbreak. Protecting against future outbreaks requires the identification of targets that are conserved between coronavirus strains and amenable to drug discovery. Two such targets are the main protease (M^pro) and the papain-like protease (PL^pro) which are essential for the coronavirus replication cycle. We describe the discovery of two non-antiviral therapeu

SUBMITTER: Redhead MA 

PROVIDER: S-EPMC8225628 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature